Pembrolizumab is the standard therapy for urothelial carcinoma treatment; however, adverse events have been noted. Here, we report a rare case of vision loss as an immune-related adverse event of pembrolizumab therapy in a patient with metastatic renal pelvic cancer.
No takes yet. Share an insight, caveat, or question.
Inoue et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: